Santen Pharmaceutical (4536.T)

Executive Summary

Santen Pharmaceutical is a Japan-based pure-play ophthalmology leader with a 130-year legacy, offering a comprehensive portfolio of prescription and OTC products for glaucoma, retinal diseases, and dry eye. The company is listed on the Nikkei 225 and holds a strong global presence across 60 countries. Key pipeline assets include DE-117B (a fixed-dose combination of a novel prostaglandin and latanoprost) in Phase 3 for open-angle glaucoma, with top-line data expected shortly after the trial's completion in March 2026. Additionally, Santen continues to expand its approved product Eybelis (omidenepag isopropyl) for normal tension glaucoma and ocular hypertension. With a market capitalization of approximately $3.9 billion, Santen remains a specialized player well-positioned to capture growth in the aging global population. However, near-term catalysts are limited to late-stage readouts and potential label expansions, which may constrain upside without major pipeline successes.

Upcoming Catalysts (preview)

• Q3 2026DE-117B Phase 3 top-line data for open-angle glaucoma and ocular hypertension70% success
• TBDPotential US/European regulatory submission for Eybelis (omidenepag isopropyl) in glaucoma50% success
• TBDPhase 2 data for diquafosol/sodium hyaluronate combination in dry eye disease (NCT06146881)40% success